Sunshine Biopharma (SBFM) Income towards Parent Company (2011 - 2026)

Sunshine Biopharma (SBFM) has reported Income towards Parent Company for 15 consecutive years, with -$1.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Income towards Parent Company rose 11.68% year-over-year to -$1.6 million; the trailing twelve-month figure through Jun 2026 stood at -$5.9 million (up 1.13% YoY), and the FY2025 full-year result was -$6.0 million, down 16.83% from the prior year.
• Income towards Parent Company slipped to -$1.6 million in Q2 2026 per SBFM's latest filing, from -$1.2 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$494300.0 in Q2 2024 and bottomed at -$23.5 million in Q4 2022.
• Historically, Income towards Parent Company has averaged -$2.5 million across 5 years, with a median of -$1.2 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Income towards Parent Company plunged 3624.47% in 2022, then surged 94.85% in 2023.
• Over 5 years, Income towards Parent Company stood at -$23.5 million in 2022, then soared by 94.85% to -$1.2 million in 2023, then slumped by 46.37% to -$1.8 million in 2024, then retreated by 21.98% to -$2.2 million in 2025, then increased by 27.72% to -$1.6 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$1.6 million, -$1.2 million, and -$2.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.